ZA201201195B - Antibodies against the ectodomain of erbb3 and uses thereof - Google Patents

Antibodies against the ectodomain of erbb3 and uses thereof

Info

Publication number
ZA201201195B
ZA201201195B ZA2012/01195A ZA201201195A ZA201201195B ZA 201201195 B ZA201201195 B ZA 201201195B ZA 2012/01195 A ZA2012/01195 A ZA 2012/01195A ZA 201201195 A ZA201201195 A ZA 201201195A ZA 201201195 B ZA201201195 B ZA 201201195B
Authority
ZA
South Africa
Prior art keywords
ectodomain
erbb3
antibodies against
antibodies
Prior art date
Application number
ZA2012/01195A
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201201195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals filed Critical Merrimack Pharmaceuticals
Publication of ZA201201195B publication Critical patent/ZA201201195B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
ZA2012/01195A 2009-08-21 2012-02-17 Antibodies against the ectodomain of erbb3 and uses thereof ZA201201195B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (1)

Publication Number Publication Date
ZA201201195B true ZA201201195B (en) 2015-07-29

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/01195A ZA201201195B (en) 2009-08-21 2012-02-17 Antibodies against the ectodomain of erbb3 and uses thereof

Country Status (21)

Country Link
EP (1) EP2467164A2 (en)
JP (1) JP5752687B2 (en)
KR (1) KR20120059568A (en)
CN (1) CN103002912A (en)
AU (1) AU2010284018C1 (en)
BR (1) BR112012003809A2 (en)
CA (1) CA2771744A1 (en)
CR (1) CR20120108A (en)
DO (1) DOP2012000044A (en)
EA (1) EA201200195A1 (en)
EC (1) ECSP12011740A (en)
IL (1) IL218097A0 (en)
IN (1) IN2012DN01518A (en)
MA (1) MA33582B1 (en)
MX (1) MX336091B (en)
NI (1) NI201200027A (en)
PE (1) PE20121585A1 (en)
SG (1) SG178509A1 (en)
TN (1) TN2012000057A1 (en)
WO (1) WO2011022727A2 (en)
ZA (1) ZA201201195B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (en) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2896632B1 (en) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
HUE029026T2 (en) 2009-12-22 2017-01-30 Roche Glycart Ag ANTI-HER3 Antibodies and uses thereof
PL2544680T3 (en) 2010-03-11 2015-08-31 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative breast cancer
SG184452A1 (en) 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
PE20140230A1 (en) 2010-08-20 2014-02-26 Novartis Ag ANTIBODIES TO THE EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
IT1402149B1 (en) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS.
CA2816519C (en) 2010-11-01 2019-01-15 Symphogen A/S Pan-her antibody composition
KR20140138353A (en) 2011-04-19 2014-12-03 메리맥 파마슈티컬즈, 인크. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
CN103781800A (en) 2011-06-20 2014-05-07 协和发酵麒麟株式会社 Anti-erbB3 antibody
IN2014CN03042A (en) 2011-09-30 2015-07-03 Regeneron Pharma
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
AU2012335543C1 (en) * 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
UY34487A (en) 2011-12-05 2013-07-31 Novartis Ag ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEIVER 3 (HER3)
WO2013124297A1 (en) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2015058108A1 (en) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
SG11201607109QA (en) * 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
CN110642952B (en) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 anti-HER 3 antibody, preparation method and application thereof
CA2959775A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
DK3365373T3 (en) 2015-10-23 2021-04-06 Merus Nv BINDING MOLECULES THAT INHIBIT CANCER GROWTH
IL269656B1 (en) 2017-03-31 2024-02-01 Merus Nv Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
MA49846A (en) 2017-08-09 2020-06-17 Merus Nv ANTIBODIES THAT BOUND TO EGFR AND CMET
CA3072267A1 (en) 2017-08-09 2019-02-14 University Of Saskatchewan Her3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
WO2019241893A2 (en) * 2018-06-22 2019-12-26 Crd Pharmaceuticals Inc Anti-her3 antibody and uses thereof
CA3196940A1 (en) * 2020-10-14 2022-04-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (en) * 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
NI201200027A (en) 2013-01-29
EA201200195A1 (en) 2012-12-28
TN2012000057A1 (en) 2013-09-19
EP2467164A2 (en) 2012-06-27
PE20121585A1 (en) 2012-11-29
DOP2012000044A (en) 2012-06-30
IL218097A0 (en) 2012-04-30
ECSP12011740A (en) 2013-02-28
WO2011022727A2 (en) 2011-02-24
MA33582B1 (en) 2012-09-01
AU2010284018A1 (en) 2012-03-22
AU2010284018B2 (en) 2014-06-05
MX336091B (en) 2016-01-08
SG178509A1 (en) 2012-04-27
CA2771744A1 (en) 2011-02-24
IN2012DN01518A (en) 2015-06-05
BR112012003809A2 (en) 2019-09-24
WO2011022727A3 (en) 2013-06-27
JP5752687B2 (en) 2015-07-22
AU2010284018C1 (en) 2015-10-15
CR20120108A (en) 2012-06-05
JP2013506622A (en) 2013-02-28
MX2012002172A (en) 2012-05-29
KR20120059568A (en) 2012-06-08
CN103002912A (en) 2013-03-27

Similar Documents

Publication Publication Date Title
ZA201201195B (en) Antibodies against the ectodomain of erbb3 and uses thereof
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) Anti-glp-1r antibodies and their uses
HRP20170973T1 (en) Anti-c4.4a antibodies and uses thereof
SI2946791T1 (en) Anti-CD277 antibodies and uses thereof
HK1176948A1 (en) Antibodies against human csf-1r and uses thereof csf-1r
SI2516468T1 (en) Anti-flt3 antibodies and methods of using the same
HK1179981A1 (en) Antibodies against il-18r1 and uses thereof il-18r1
EP2427479A4 (en) Antibodies and methods of use thereof
HRP20181973T1 (en) Improved anti human fraktalkine antibodies and uses thereof
EP2611832A4 (en) Anti-cxcl13 antibodies and methods of using the same
HK1195776A1 (en) Anti-51 antibodies and uses thereof -51
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
EP2632952A4 (en) Anti-sod1 antibodies and uses thereof
SG10201501285RA (en) Anti-alpha2 integrin antibodies and their uses
EP2507263A4 (en) Anti-igf-ir antibodies and uses thereof
GB0903151D0 (en) Antibody uses and methods
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
EP2545378A4 (en) Anti-lg3 antibodies and uses thereof
GB0906115D0 (en) Antibody and uses thereof